Chief Medical Officer
Be Biopharma
San Francisco, California, United States
Dr. Wing-Yen Wong, Interim CMO at Be Biopharma, is an experienced physician, clinical scientist and drug developer with over 20 years of successful product development across early to late-stage development and medical affairs. She is a treating physician with experience in treating patients with hemophilia, sickle cell disease and pediatric hematology/oncology. She has played pivotal roles in the development and approval of various therapies including: the first gene therapy for Hemophilia A (Roctavian), FEIBA, Advate, Adynovate, Eloctate, Alprolix, Rixubis, Obizur, and the first recombinant von Willebrand factor (Vonvendi).
Dr. Wong was previously Group Vice-President of Global Medical Affairs and Scientific Strategy at BioMarin and led the development and approval of Roctavian for Hemophilia A. Dr. Wong provided ground-breaking leadership in the design and oversight of over six years of the AAV5 clinical trials reported in NEJM publications including the largest Phase 3 clinical trial in gene therapy for Hemophilia to date. Prior to BioMarin, Dr. Wong was Vice President of Global Medical and Head of Clinical Research of Hemophilia at Biogen and Baxter.
Dr. Wong spent over 15 years as a practicing clinician and professor at Children’s Hospital Los Angeles and the Los Angeles County and USC Medical Center. As a clinician, Dr. Wong presented and published numerous studies and papers on her research in hemophilia and hematology and has served as a reviewer for leading medical journals. In 2003, Dr. Wong was appointed by the Secretary of Health and Human Services as a member of the Advisory Committee on Blood Safety and Availability.
Dr. Wong earned her M.D. at the USC Keck School of Medicine and a BA at Occidental College. She served a Fellowship at the LAC and USC Medical Center in pediatric hematology-oncology and is an Associate Professor of Pediatrics at the University of Southern California.